FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952764324> ?p ?o ?g. }

• W2952764324 endingPage "11" @default.
• W2952764324 startingPage "1" @default.
• W2952764324 abstract "PURPOSE Although aromatase inhibitor (AI) treatment is effective in estrogen receptor–positive postmenopausal breast cancer, resistance is common and incompletely explained. Genomic instability, as measured by somatic copy number alterations (SCNAs), is important in breast cancer development and prognosis. SCNAs to specific genes may drive intrinsic resistance, or high genomic instability may drive tumor heterogeneity, which allows differential response across tumors and surviving cells to evolve resistance to treatment rapidly. We therefore evaluated the relationship between SCNAs and intrinsic resistance to treatment as measured by a poor antiproliferative response. PATIENTS AND METHODS SCNAs were determined by single nucleotide polymorphism array in baseline and surgery core-cuts from 73 postmenopausal patients randomly assigned to receive 2 weeks of preoperative AI or no AI in the Perioperative Endocrine Therapy—Individualizing Care (POETIC) trial. Fifty-six samples from the AI group included 28 poor responders (PrRs, less than 60% reduction in protein encoded by the MKI67 gene [Ki-67]) and 28 good responders (GdRs, greater than 75% reduction in Ki-67). Exome sequencing was available for 72 pairs of samples. RESULTS Genomic instability correlated with Ki-67 expression at both baseline ( P < .001) and surgery ( P < .001) and was higher in PrRs ( P = .048). The SCNA with the largest difference between GdRs and PrRs was loss of heterozygosity observed at 17p (false discovery rate, 0.08), which includes TP53. Nine of 28 PrRs had loss of wild-type TP53 as a result of mutations and loss of heterozygosity compared with three of 28 GdRs. In PrRs, somatic alterations of TP53 were associated with higher genomic instability, higher baseline Ki-67, and greater resistance to AI treatment compared with wild-type TP53. CONCLUSION We observed that primary tumors with high genomic instability have an intrinsic resistance to AI treatment and do not require additional evolution to develop resistance to estrogen deprivation therapy." @default.
• W2952764324 created "2019-06-27" @default.
• W2952764324 creator A5006665510 @default.
• W2952764324 creator A5019349196 @default.
• W2952764324 creator A5023812122 @default.
• W2952764324 creator A5035383163 @default.
• W2952764324 creator A5039141367 @default.
• W2952764324 creator A5043736497 @default.
• W2952764324 creator A5057689412 @default.
• W2952764324 creator A5062099405 @default.
• W2952764324 creator A5064188148 @default.
• W2952764324 creator A5073889721 @default.
• W2952764324 creator A5084993667 @default.
• W2952764324 creator A5090040523 @default.
• W2952764324 date "2019-12-01" @default.
• W2952764324 modified "2023-10-03" @default.
• W2952764324 title "Genomic Instability and<i>TP53</i>Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment" @default.
• W2952764324 cites W1650330593 @default.
• W2952764324 cites W1995056702 @default.
• W2952764324 cites W2005895632 @default.
• W2952764324 cites W2006288875 @default.
• W2952764324 cites W2020099456 @default.
• W2952764324 cites W2047687247 @default.
• W2952764324 cites W2096283457 @default.
• W2952764324 cites W2102619694 @default.
• W2952764324 cites W2108643617 @default.
• W2952764324 cites W2113435829 @default.
• W2952764324 cites W2115724079 @default.
• W2952764324 cites W2115919763 @default.
• W2952764324 cites W2116802246 @default.
• W2952764324 cites W2123945948 @default.
• W2952764324 cites W2130594114 @default.
• W2952764324 cites W2141563900 @default.
• W2952764324 cites W2144775044 @default.
• W2952764324 cites W2150134401 @default.
• W2952764324 cites W2163042952 @default.
• W2952764324 cites W2320186989 @default.
• W2952764324 cites W2375577403 @default.
• W2952764324 cites W2550144082 @default.
• W2952764324 cites W2574190322 @default.
• W2952764324 cites W2742281710 @default.
• W2952764324 cites W2743649404 @default.
• W2952764324 doi "https://doi.org/10.1200/po.18.00286" @default.
• W2952764324 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7446335" @default.
• W2952764324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32914010" @default.
• W2952764324 hasPublicationYear "2019" @default.
• W2952764324 type Work @default.
• W2952764324 sameAs 2952764324 @default.
• W2952764324 citedByCount "0" @default.
• W2952764324 crossrefType "journal-article" @default.
• W2952764324 hasAuthorship W2952764324A5006665510 @default.
• W2952764324 hasAuthorship W2952764324A5019349196 @default.
• W2952764324 hasAuthorship W2952764324A5023812122 @default.
• W2952764324 hasAuthorship W2952764324A5035383163 @default.
• W2952764324 hasAuthorship W2952764324A5039141367 @default.
• W2952764324 hasAuthorship W2952764324A5043736497 @default.
• W2952764324 hasAuthorship W2952764324A5057689412 @default.
• W2952764324 hasAuthorship W2952764324A5062099405 @default.
• W2952764324 hasAuthorship W2952764324A5064188148 @default.
• W2952764324 hasAuthorship W2952764324A5073889721 @default.
• W2952764324 hasAuthorship W2952764324A5084993667 @default.
• W2952764324 hasAuthorship W2952764324A5090040523 @default.
• W2952764324 hasBestOaLocation W29527643241 @default.
• W2952764324 hasConcept C104317684 @default.
• W2952764324 hasConcept C121608353 @default.
• W2952764324 hasConcept C126322002 @default.
• W2952764324 hasConcept C134305767 @default.
• W2952764324 hasConcept C135763542 @default.
• W2952764324 hasConcept C143425029 @default.
• W2952764324 hasConcept C143589142 @default.
• W2952764324 hasConcept C143998085 @default.
• W2952764324 hasConcept C178169997 @default.
• W2952764324 hasConcept C180754005 @default.
• W2952764324 hasConcept C502942594 @default.
• W2952764324 hasConcept C530470458 @default.
• W2952764324 hasConcept C54355233 @default.
• W2952764324 hasConcept C552990157 @default.
• W2952764324 hasConcept C71924100 @default.
• W2952764324 hasConcept C86803240 @default.
• W2952764324 hasConceptScore W2952764324C104317684 @default.
• W2952764324 hasConceptScore W2952764324C121608353 @default.
• W2952764324 hasConceptScore W2952764324C126322002 @default.
• W2952764324 hasConceptScore W2952764324C134305767 @default.
• W2952764324 hasConceptScore W2952764324C135763542 @default.
• W2952764324 hasConceptScore W2952764324C143425029 @default.
• W2952764324 hasConceptScore W2952764324C143589142 @default.
• W2952764324 hasConceptScore W2952764324C143998085 @default.
• W2952764324 hasConceptScore W2952764324C178169997 @default.
• W2952764324 hasConceptScore W2952764324C180754005 @default.
• W2952764324 hasConceptScore W2952764324C502942594 @default.
• W2952764324 hasConceptScore W2952764324C530470458 @default.
• W2952764324 hasConceptScore W2952764324C54355233 @default.
• W2952764324 hasConceptScore W2952764324C552990157 @default.
• W2952764324 hasConceptScore W2952764324C71924100 @default.
• W2952764324 hasConceptScore W2952764324C86803240 @default.
• W2952764324 hasIssue "3" @default.
• W2952764324 hasLocation W29527643241 @default.
• W2952764324 hasLocation W29527643242 @default.

• next